Sensorion News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

07.08.19	Sensorion Announces Appointment of John Furey, Former COO of Spark Therapeutics, as Independent Board Member (Businesswire)
31.07.19	Sensorion: Reporting of the General Assembly Appointment of Three New Directors (Businesswire)
12.07.19	Sensorion Receives FDA IND Approval for Arazasetron (SENS-401) (Businesswire)
01.07.19	Sensorion Announces an Oral Presentation at the 5th Congress of European ORL-Head & Neck Surgery in Brussels (Businesswire)
28.06.19	Sensorion Receives European Medicines Agency Agreement on the Pediatric Investigation Plan (PIP) for Arazasetron (SENS-401) in Two Indications (Businesswire)
12.06.19	Sensorion Announces a €20m Convertible Bond Issue Subscribed by Two Renowned Investors Invus and Sofinnova Partners (Businesswire)
03.06.19	Sensorion Announces Poster Presentation at the "Société Internationale d’Otoneurologie” Symposium (Businesswire)
29.05.19	Sensorion: Reporting of the General Assembly (Businesswire)
27.05.19	Sensorion Announces the Signature of a Partnership Framework Agreement with Institut Pasteur on Gene Therapy Programs Targeting Hearing Loss (Businesswire)
17.05.19	Sensorion announces oral presentation at the European Histamine Research Society (Businesswire)
15.05.19	Sensorion Announces the Positive Data Safety Monitoring Board (DSMB) Review and Continuation of the Phase 2 Clinical Trial for SENS-111 in Acute Unilateral Vestibulopathy (AUV) (Businesswire)
27.03.19	Sensorion Reports Its 2018 Annual Results; 75% of Patients Enrolled in the Sens-111 Clinical Trial (Businesswire)
11.03.19	Sensorion strengthens its financial structure by issuing a €4.7 million nominal bond issue subscribed by new European investors and management (Businesswire)
14.02.18	Sensorion Presents New SENS-401 Data at ARO 2018 MidWinter Meeting (Businesswire)
24.01.18	Sensorion Announces Multiple Poster Presentations at the ARO 2018 MidWinter Meeting (Businesswire)
21.12.17	Sensorion Successfully Closes on a €1.6 Million Euro Placement with Cochlear (Businesswire)
20.12.17	Sensorion to Participate in Corporate Access Event in San Francisco, January 8 – 10, 2018 (Businesswire)
18.12.17	Sensorion and Cochlear Announce Collaboration to Study Combination Therapies for Cochlear Implant Patients (Businesswire)
18.10.17	Sensorion Reports 2017 First-Half Results (Businesswire)
11.09.17	Sensorion’s Oral SENS-401 Prevented Cisplatin-Induced Hearing Loss By More Than 50 Percent in Preclinical Study (Businesswire)
22.08.17	Sensorion Announces FDA Orphan Drug Designation Granted to SENS-401 for Treatment of Cisplatin-Induced Ototoxicity in Pediatric Patients (Businesswire)
02.05.17	Sensorion Presents Preclinical Data for SENS-401 Demonstrating Protection against Cisplatin-Induced Hearing Loss in Animal Model (Businesswire)
14.03.17	Sensorion Reports Full Year 2016 Results in Line with Status of Clinical Development (Businesswire)
09.03.17	Sensorion Receives European Authorization to Initiate Phase II Clinical Trial of SENS-111 to Treat Acute Vertigo (Businesswire)
29.11.16	Sensorion to Initiate a Phase 2 Clinical Trial with SENS-111, its Drug Candidate for Acute Severe Vertigo (Businesswire)
24.11.16	Sensorion Receives Orphan Drug Designation in Europe for SENS-401 in Sudden Sensorineural Hearing Loss (Businesswire)
17.11.16	Sensorion Presents New Preclinical Results with SENS-401 in Acute Sensorineural Hearing Loss at Neuroscience 2016 (Businesswire)
17.10.16	Sensorion Obtains a Positive Opinion on Granting of Orphan Medicinal Product Designation for SENS-401 in Europe (Businesswire)
13.10.16	Sensorion: 2016 First-Half Results (Businesswire)
06.10.16	Sensorion Presented Data from the Caloric Test with SENS-111 at the EACPT Conference (Businesswire)
29.09.16	Sensorion Selects New Drug Candidate, SENS-401, to Treat Vestibular and Auditory Disorders Associated with Inner Ear Lesions (Businesswire)
21.09.16	Sensorion: Initial Results of Phase 1b Clinical Study on SENS-111 presented at the AAO-HNSF Annual Meeting in San Diego (Businesswire)
19.09.16	Sensorion Presents Results of 2 Preclinical Trials at the 2016 IEB congress (Businesswire)
07.09.16	Sensorion Announces Positive Results From SENS-218 Phase 1 Clinical Trial Undertaken in the UK (Businesswire)
07.09.16	Sensorion Announces Positive Results From SENS-218 Phase 1 Clinical Trial Undertaken in the UK (Businesswire)
01.09.16	Sensorion to Present at the 18th Annual Rodman & Renshaw Global Investment Conference (Businesswire)
01.09.16	Sensorion Obtains FDA Approval to Initiate a Clinical Study of SENS-111 in Acute Severe Vertigo (Businesswire)
01.09.16	Sensorion Obtains FDA Approval to Initiate a Clinical Study of SENS-111 in Acute Severe Vertigo (Businesswire)
17.08.16	Sensorion Strengthens Its Financial Structure with the Exercise of the Second Tranche of Its Financing Agreement (Businesswire)
12.05.16	Sensorion to Present Data from Phase 1b Clinical Trial of SENS-111 at AAO-HNSF Annual Meeting (Businesswire)
17.03.16	Sensorion Reports 2015 Annual Results in line with the Company’s Development (Businesswire)
22.02.16	Sensorion Presents SENS-218 Data at Association for Research in Otolaryngology Meeting (Businesswire)
22.02.16	Sensorion Presents SENS-218 Data at Association for Research in Otolaryngology Meeting (Businesswire)
11.02.16	Sensorion Receives French Tech Pass Certification (Businesswire)
11.02.16	Sensorion Receives French Tech Pass Certification (Businesswire)
08.02.16	Sensorion Provides 2016 Financial Calendar (Businesswire)
06.01.16	Sensorion Receives Approval from the UK Drug Agency to Initiate Clinical Trial of SENS-218 (Businesswire)
19.11.15	Sensorion: Positive Results Obtained in Phase 1b of the Clinical Study on SENS-111 and Setting up of Additional Funding (Businesswire)
20.10.15	Sensorion Has Presented an Abstract on Recovering Hearing Loss at the Neuroscience 2015 Annual Meeting in Chicago (Businesswire)
20.07.15	Sensorion Successfully Closes an €8 Million International Private Placement to Accelerate Its Development Strategy (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Logitech Intl	82.24	2.93 %	K V
Part Grp Hldg	1’404.00	1.67 %	K V
CieFinRichemont	170.10	1.10 %	K V
Kuehne+Nagel Int	206.60	0.98 %	K V
Holcim	89.82	0.92 %	K V
ABB	53.58	0.04 %	K V
Givaudan	3’941.00	-0.10 %	K V
Geberit	498.50	-0.46 %	K V
Alcon	80.46	-0.54 %	K V
Sonova Hldg	314.80	-1.16 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Sensorion SA

Aktien Top/Flop

Meistgelesene Nachrichten